Acelyrin, Inc.
NASDAQ: SLRN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mina Kim
- Employees
- 83
- Headquarters
- Agoura Hills, United States
- IPO year
- 2023
- Market cap
- $229.2M
- Website
- https://www.acelyrin.com
Loading SLRN…
Loading profile data…Frequently asked questions about SLRN
What does Acelyrin, Inc. (SLRN) do?
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase...
Where does SLRN trade?
Acelyrin, Inc. (SLRN) trades on the NASDAQ Global Select.
What sector is SLRN in?
Acelyrin, Inc. (SLRN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Acelyrin, Inc.?
Mina Kim is the chief executive officer of Acelyrin, Inc. (SLRN).
Where is Acelyrin, Inc. headquartered?
Acelyrin, Inc. is headquartered in United States.
Does SLRN pay a dividend?
Acelyrin, Inc. (SLRN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLRN go public?
Acelyrin, Inc. (SLRN) completed its initial public offering in 2023.